Biopharma
A billionaire-seeded Swiss "hallmarks-of-aging" holdco that quietly went dark — rebranded to Centenara in Sep-2024, lead eye asset terminated, holdco comms silent ~21 months; the ONLY live value driver is a separately-financed Belgian portco (Rejuvenate Biomed RJx-01, Ph2 COPD-sarcopenia, topline end-2026). Un-investable as a private until an IPO path or a single de-risked asset emerges; WATCHING the RJx-01 readout only.
Research
The verdict
A billionaire-seeded Swiss "hallmarks-of-aging" holdco that quietly went dark — rebranded to Centenara in Sep-2024, lead eye asset terminated, holdco comms silent ~21 months; the ONLY live value driver is a separately-financed Belgian portco (Rejuvenate Biomed RJx-01, Ph2 COPD-sarcopenia, topline end-2026). Un-investable as a private until an IPO path or a single de-risked asset emerges; WATCHING the RJx-01 readout only.
Business model — a longevity holdco / venture-builder, not a single-asset biotech. Rejuveron/Centenara was founded in 2019 in Schlieren-Zürich (Bio-Technopark) by entrepreneurial scientist Matthias Steger and billionaire investor Christian Angermayer (Apeiron). Its model: "create or acquire innovative programs, each held within a wholly-owned or majority-owned company," with a central drug-discovery/development team applying the biology of aging to "prevent, repair, or reverse the hallmarks of aging". This is a hub-and-spoke / aggregator structure (analogous to Roivant's "vant" model, or to BridgeBio's hub-and-spoke, but at seed/Series-A scale and aimed at aging hallmarks rather than rare disease).
The portfolio (the actual "products"). Six named portfolio companies:
| Portco | Geography | Modality / target | Lead asset | Furthest stage (as known) |
|---|---|---|---|---|
| Endogena Therapeutics | CH / US / Canada | Small-molecule endogenous stem-cell regeneration | EA-2353 (retinitis pigmentosa); EA-2351 (geographic atrophy / dry AMD) | Ph1/2a completed then terminated (RP) |
| Rejuvenate Biomed | Belgium | Multi-pathway combination drug (galantamine + metformin) | RJx-01 (sarcopenia / COPD muscle wasting) | Ph2 recruitment complete Jun-2026, topline end-2026 |
| Rejuveron Senescence Therapeutics (RejuverSen S.L.) | CH / Spain (Barcelona) | Senolytic biologic (immune clearance of senescent cells) | RST-001 (senescence post-TNBC chemo); RST-002 (CKD/IPF) | IND-enabling; clinic targeted 2025 |
| Rejuveron Telomere Therapeutics | Switzerland | Oral small molecule restoring telomeres | undisclosed (dyskeratosis congenita) | Pre-clinical |
| Rejuveron Vascular Therapeutics | Switzerland | Brain-vasculature repair | undisclosed | Pre-clinical |
| Boost Neuroscience | US | Synapse regeneration (founded by Nobel laureate Thomas Südhof) | undisclosed | Early / stake acquired |
Customers / suppliers / contract structure. As a pre-revenue holdco, it has no customers and no commercial revenue — n/a — private, pre-revenue. Its "suppliers" are CDMOs/CROs (undisclosed). Its "contract structure" is the cap table of each portco plus in-licensing deals (e.g., RejuverSen in-licensed IP from Prof. Manuel Serrano's prior startup Senolytic Therapeutics; Boost Neuroscience built on Südhof's IP). Revenue, if any, would eventually come from out-licensing / partnering / portco exits, not product sales by the holdco.
Plain-terms summary. This is a billionaire-backed aging-biotech incubator that spreads a modest war-chest (~$76M disclosed, see Lens 5) across six shots on goal at the hallmarks of aging, hoping one portco produces a clinical winner it can license or float. The thesis is portfolio-diversified ("we don't know which hallmark cracks first, so own several"); the risk is that thin per-asset capital means none of the shots is fully funded to a value-inflection readout from the holdco alone.
There is no physical supply chain in the operating-company sense — names or it didn't happen, and here the honest answer is most nodes are undisclosed. What can be named:
n/a — specific CDMOs not disclosed.Claimed moats:
Reality check on durability. None of these is a durable competitive moat in the Buffett sense. The science moats live inside the portcos, not the holdco — and several portcos are also externally financed (Rejuvenate Biomed runs its own Series B), so the holdco's economic claim is partial. Bargaining power: low — a sub-$100M-raised holdco has little leverage over CDMOs, regulators, or future pharma licensees; it is a price-taker for capital and partnering terms. Switching costs / network effects: none. The honest moat verdict: a credibility-and-capital network, not a structural moat — which is exactly the kind of "moat" that evaporates when the capital cycle turns (and in aging biotech, 2023–2025, it turned hard — see Lens 12/13).
No revenue, EBITDA, or earnings exist to break out — n/a — pre-revenue, no segment financials (the holdco files no public accounts; segments.csv is header-only). The meaningful "segmentation" is by aging-hallmark / therapeutic area, with the capital implicitly concentrated where clinical stage is furthest:
Trend & cause. The center of gravity has shifted from the eye (Endogena, decelerating/terminated) to muscle (Rejuvenate Biomed, the only one accelerating), but that shift is involuntary — it reflects the eye asset breaking, not a strategic pivot. The holdco's own engine (Telomere, Vascular, Boost) shows no public clinical progress since 2023.
(+private overlay: Lens 5 → funding/valuation trajectory; Lens 7 → cap table & secondary marks; Lens 8 → funding/product events. +clinical overlay: pipeline-by-phase woven through.)
There is no earnings print — the performance signal for a private is the financing trajectory, and here it tells a stalling story.
| Round / event | Date | Amount | Valuation | Lead / notable investors | Source |
|---|---|---|---|---|---|
| Founding | 2019 | — | — | Steger + Angermayer (Apeiron) | |
| Early/Series A (first tracked round) | ~25-Mar-2021 | undisclosed (part of ~$76M total) | — | Apeiron + syndicate | |
| Series B + convertible loan (dual tranche) | 13-Sep-2023 | $75M | ~$400M post-money | Co-led Catalio Capital (Druckenmiller/Howard-backed) + Apeiron; Mubadala Capital joined | |
| Total disclosed raised | (cumulative) | ~$76.3M over 2 main rounds (Tracxn); some trackers cite up to ~$163M lifetime incl. portco-level rounds (CBInsights) | — | 14 investors incl. Gaingels |
Burn / runway signal (the real performance tell). The Series B closed Sep-2023. For a six-spoke holdco running multiple Ph1/2 trials, $75M is thin — rough burn for a holdco of this footprint is **$25–40M/yr** across spokes, implying the Sep-2023 cash reached **roughly into 2025–2026** before needing a top-up. The **Sep-2024 rebrand + silence thereafter** (no funding, no clinical PR for ~21 months at the holdco) is consistent with **a capital wall hit during the 2024–2025 longevity-funding winter** — the single most important "performance" datapoint in this dossier. *(This is an inference from the absence of news + known round timing, labeled; it is not a confirmed insolvency.)*
No earnings calls exist. The sentiment proxy is founder/CEO public communication, and the trend is loud-then-silent:
Recurring phrases they used: "hallmarks of aging," "healthspan and lifespan," "prevent, repair, reverse," "diversified across modalities/stages." What they stopped saying: anything about new financings, new clinical milestones, or the Abu Dhabi expansion. The tone shift from expansive-fundraising to silence is the clearest negative sentiment signal available.
Cap-table quality (the +private lens):
n/a — none disclosed (no public mark-to-market; this is exactly what a crossover round would have provided and didn't).Mechanism comps (the +clinical lens — comps by target, not by P/E):
| Mechanism / area | Closest comparable | What its fate tells you |
|---|---|---|
| Senolytics (RejuverSen RST-001/002) | Unity Biotechnology — most prominent senolytic pure-play | Shuttered Sep-2024 after lead OA program failed Ph2 (vs placebo, 2020). Brutal read-across for senolytic value. |
| Cellular rejuvenation / reprogramming | Altos Labs (~$5B+, Bezos); Retro Biosciences (chasing ~$5B, Altman); NewLimit (Armstrong) | Capital is flooding to reprogramming, not to small-molecule/biologic hallmark plays — Rejuveron is on the out-of-favor side of the longevity split. |
| Drug-repurposing geroscience (Rejuvenate Biomed = metformin + galantamine) | TAME trial (metformin, 3,000 pts, AFAR); SGLT2i geroscience interest | Validates the repurposing thesis academically, but no approved "aging" indication exists — RJx-01 must win a conventional disease endpoint (COPD-sarcopenia), not an "aging" claim. |
| Eye / stem-cell regeneration (Endogena) | broad ophthalmic gene/cell therapy field | Lead RP asset terminated — the comp here is the company's own failed program. |
P/E, EV/Sales, EV/EBITDA, dividend yield, 5-yr ROE: n/a — private, pre-revenue, no public financials. Fabricating any multiple here would be the single most damaging error; none is offered.
No stock exists, so the proxy is events that materially moved the company's trajectory / external marks over ~5 years [all web]:
Pattern read: the company's value moved on (a) marquee financings and (b) portco clinical firsts. Post-2023 it stopped generating (a) entirely and generates (b) only via Rejuvenate Biomed. The market (here, the private-capital market) reacts to fresh capital and de-risking readouts — Rejuveron has produced neither at the holdco level for ~2 years.
(+clinical addition: Science & exclusivity sub-section appended.)
Capital-allocation history. The defining decision — spreading ~$76M across six spokes — looks, with hindsight, like over-diversification with under-capitalization: thin enough per asset that none was funded to a clean value-inflection readout from the holdco, and broad enough that the team's attention was split. The near-majority $20M top-up into Endogena concentrated capital into what became the terminated eye program — a poor allocation outcome (though judged ex-post). ROE/ROIC: n/a — pre-revenue.
Red flags (management): (1) founder's edge is promotion/finance, not drug delivery; (2) ~21-month communication blackout; (3) key co-founder's focus drifting into the impaired spoke; (4) generic-rebrand-as-reset; (5) thin/low-visibility holdco CEO. None is fraud-grade — collectively they paint a stalled, capital-starved venture, not a scandal.
Accounting forensics: n/a — no public financial statements. As a Swiss private AG, Rejuveron/Centenara files no public income statement, balance sheet, or cash-flow statement; financials.csv is header-only. There is nothing to forensically analyze for revenue-recognition, receivables/inventory divergence, SBC-flattering-non-GAAP, or goodwill — the usual surfaces don't exist. The single "forensic" concern that can be raised is going-concern: the funding silence + asset termination + comms blackout are classic pre-distress markers for a private biotech, though unconfirmed.
Regulatory findings (required sub-section).
companies/rejuveron/regulatory/regulatory-findings.md, total_sec_findings: 0 — Rejuveron has no CIK (private, not an SEC filer), so no Litigation Releases or AAERs are possible or found."Rejuveron" OR "Centenara Labs" (FTC OR DOJ OR FDA … enforcement) returned no material hits — no settlements, fines, penalties, consent decrees, or lawsuits against either entity surfaced.n/a — no 10-K exists (private, no EDGAR filings).n/a — patent/LOE timing not disclosed.(+clinical swap: Lens 11 → rNPV + runway-to-catalyst; no EPS line, no forecast.ts create in unattended mode.)
No EPS projection is possible or appropriate (pre-revenue private; no shares trade). The two questions that matter for a +clinical +private name are (a) what is the lead asset worth risk-adjusted, and (b) does cash reach the next value-inflection catalyst?
(a) Lead-asset rNPV — illustrative, heavily caveated ``. The only asset near a value-inflection readout is Rejuvenate Biomed RJx-01 (Ph2 MINT-COPD, topline end-2026). A back-of-envelope rNPV:
(b) Runway-to-catalyst — the binding question, and the answer looks adverse. The holdco's last disclosed capital was the Sep-2023 $75M; no top-up has surfaced in ~21 months. `` burn across six spokes likely exhausted holdco-level cash around 2025–2026. The next true value-inflection catalyst is the RJx-01 Ph2 topline (end-2026) — but that trial is funded at the Rejuvenate Biomed level (its own €15.7M Series B), not by the holdco. So: the holdco may not have runway to its own next catalyst, while the one catalyst that exists is ring-fenced inside a partially-owned spoke. This is the crux of the bear case.
Brier forecast: not logged (unattended --watchlist mode — per skill, only log a forecast on genuine committed conviction; this WATCHING-grade private does not qualify, and no binary the holdco controls has a clean public resolution source).
Bull case. Aging is the largest addressable "indication" in medicine, and a diversified portfolio of credible-scientist-founded shots (Serrano, Südhof) is a cheap call option on the hallmarks-of-aging thesis. The cap table (Apeiron, Catalio/Druckenmiller-Howard, Mubadala) can fund another round if one spoke de-risks. RJx-01's Ph2 topline (end-2026) is a near-term, binary, potentially-positive catalyst in a real disease (COPD-sarcopenia) with a clean Ph1b behind it; a win could re-rate the whole platform and reopen financing. Repurposed generics = cheap to develop, fast to approve, real reimbursement path. If the longevity-capital winter thaws (Retro/Altos megarounds show the theme is alive), a credible aging holdco with a Ph2 asset is a re-financeable story.
Bear case (the dominant case). (1) The holdco has gone dark for ~21 months — no financing, no clinical PR, key co-founder's attention drifted into the terminated eye spoke; this is the signature of a capital-starved, stalling venture. (2) Its furthest-advanced asset isn't really "its" — RJx-01 sits in a separately-financed Belgian portco; the holdco's attributable economics are a fraction. (3) The senescence leg is read-across-impaired by Unity Biotechnology's Ph2 failure + 2024 shutdown — the field's flagship cautionary tale. (4) Over-diversified, under-capitalized: ~$76M across six spokes funded none to a clean readout. (5) No crossover investors → no IPO path → no liquidity for any position taken.
Pre-mortem (it's late-2027, the thesis broke — what happened?): RJx-01's Ph2 missed or was ambiguous (the metformin-muscle paradox bit); the holdco couldn't raise a Series C into a frozen longevity-capital market; spokes were wound down or sold for parts; "Centenara" quietly delisted from the longevity directories like Endogena did. The rebrand was the last narrative reset before dormancy.
Are multiples too high? n/a — no public multiple. The ~$400M Series-B post-money (Sep-2023) now looks stale and likely above any 2026 mark given the funding winter and the eye-asset termination; a fresh round would plausibly be a down round if it happened at all.
Contrarian view (what the market refuses to see): Both bulls and bears may be over-indexing on the holdco. The only thing that matters here is one number — RJx-01's Ph2 COPD-sarcopenia topline at end-2026 — and that's a conventional-pharma muscle-wasting bet wearing a longevity costume. Strip the "hallmarks of aging" branding and you have a single repurposed-generic Ph2 readout in a partially-owned spoke; price it as that, not as a longevity platform.
What structurally breaks the way it "makes money"? It doesn't make money, and its only economic engine (portco exits) requires capital it has stopped visibly raising. Concentration: value is concentrated in one Ph2 asset it only partly owns — if RJx-01 misses, there is no second near-term shot, and the senescence/telomere/vascular/synapse legs are pre-clinical and effectively unfunded. Weakest-moat reality: the "moat" is a network of famous advisors and rich investors — not a structural asset — and that network's defining 2024 datapoint was a rebrand-then-silence. Most dangerous competitor bulls underrate: not Altos or Retro (different modality) — it's the funding market itself + the senolytic graveyard (Unity), which has repriced the whole "kill-senescent-cells / repair-hallmarks" wager downward. Worst capital-allocation move: concentrating a $20M near-majority top-up into Endogena, whose lead RP asset was then terminated. Assumptions that must hold for today's (~$400M) mark: that a Series C closes, that RJx-01 hits, and that longevity capital re-thaws — none currently in evidence. If growth/readout disappoints 20–30%: for a private with no revenue, a soft Ph2 doesn't "cut growth" — it removes the only re-financing catalyst, and the realistic outcome is wind-down or sale-for-parts, i.e. a permanent impairment scenario that is plausible, not tail. The single scenario that permanently impairs: RJx-01 Ph2 miss + frozen Series C → dormancy. Plausibility: meaningful (not remote).
The best operating asset in pharma trading at a price that already imputes a $150B+ obesity TAM — own it on the franchise and the orforglipron/retatrutide optionality, but size for a multiple that compresses from ~30x forward as the price war and TAM-skeptic camp grind on the narrative.
The best obesity asset not yet owned by Big Pharma — but the market has already priced in a near-perfect Phase 3, leaving a binary 2027 readout where the upside is a takeout and the downside is a trap-door; SC maintenance data in Q3 2026 is the next real tell.
A cash-gushing CF monopoly priced for a successful four-engine diversification (pain, renal, gene therapy, diabetes) that is, so far, only one-third proven — own the moat, underwrite the pipeline at a discount.